AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26987738 — intervention group
Group type: EXPERIMENTAL
Intervention: Active participants managing a simulated crisis scenario (pre-test) and post-test questionnaire.
Number of subjects: 39
Study 26987738 — intervention group
Group type: COMPARATOR
Intervention: Observer participants viewing the scenario via video transmission and post-test questionnaire.
Number of subjects: 39
Study 24943088 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical clowns (MC)
Number of subjects: 91
Study 24943088 — intervention group
Group type: COMPARATOR
Intervention: Regular group (no clowns)
Number of subjects: 91
Study 21828378 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib 20 mg plus mFOLFOX6
Number of subjects: 172
Study 21828378 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib 30 mg plus mFOLFOX6
Number of subjects: 172
Study 21828378 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus mFOLFOX6
Number of subjects: 172
Study 19348529 — intervention group
Group type: EXPERIMENTAL
Intervention: High-arousing positive targets with congruent prime
Number of subjects: 0
Study 19348529 — intervention group
Group type: COMPARATOR
Intervention: Low-arousing positive targets
Number of subjects: 0
Study 17498385 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic high ligation of hernia sac
Number of subjects: 552
Study 15017668 — intervention group
Group type: EXPERIMENTAL
Intervention: Susceptibility testing-based regimens
Number of subjects: 150
Study 15017668 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy without susceptibility testing
Number of subjects: 150
Study 10866915 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 12
Study 10866915 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 12
Study 8881949 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual laser ablation with the Ultraline side‐firing Nd:YAG laser
Number of subjects: 60
Study 8881949 — intervention group
Group type: COMPARATOR
Intervention: Transurethral electroresection of the prostate (TURP)
Number of subjects: 60
Study 1579267 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of folate daily around the time of conception
Number of subjects: 0
Study 1579267 — intervention group
Group type: COMPARATOR
Intervention: Folate-free multiple vitamin
Number of subjects: 0
Study 2870808 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (650 mg) and Pentazocine (25 mg)
Number of subjects: 129
Study 2870808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 2870808 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (300 mg) and Codeine (30 mg)
Number of subjects: 129
Study 2870808 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (650 mg) and Propoxyphene Napsylate (100 mg)
Number of subjects: 129
Study 3784917 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oestrogen-progestogen therapy
Number of subjects: 136
Study 3784917 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oestrogen-progestogen therapy (all doses)
Number of subjects: 136
Study 3784917 — intervention group
Group type: EXPERIMENTAL
Intervention: All treated groups (including high-dose)
Number of subjects: 136
Study 3784917 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in daily creatinine excretion
Number of subjects: 136
Study 3784917 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 136
Study 31688157 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrashort echo-time (UTE) magnetic resonance (MR) imaging
Number of subjects: 19
Study 31688157 — intervention group
Group type: COMPARATOR
Intervention: Cone-beam computed tomography (CBCT)
Number of subjects: 19
Study 31688157 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrashort echo-time (UTE) magnetic resonance (MR) imaging and Cone-beam computed tomography (CBCT)
Number of subjects: 19
Study 30204687 — intervention group
Group type: EXPERIMENTAL
Intervention: SGA neonates
Number of subjects: 9402
Study 30204687 — intervention group
Group type: COMPARATOR
Intervention: AGA neonates
Number of subjects: 9402
Study 28237253 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of plasma rich in growth factors (PRGF)
Number of subjects: 100
Study 28237253 — intervention group
Group type: COMPARATOR
Intervention: Injection of hyaluronic acid (HA)
Number of subjects: 100
Study 26247661 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine supplementation (150 μg/day)
Number of subjects: 86
Study 26247661 — intervention group
Group type: COMPARATOR
Intervention: Control (no iodine supplementation)
Number of subjects: 86
Study 26247661 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal and cord blood thyroid tests
Number of subjects: 86
Study 26247661 — intervention group
Group type: EXPERIMENTAL
Intervention: PCB 118 exposure
Number of subjects: 86
Study 26247661 — intervention group
Group type: EXPERIMENTAL
Intervention: TBG levels
Number of subjects: 86
Study 24472478 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone plus capecitabine (40 mg/m² as a 3-hour intravenous infusion every 3 weeks plus 1000 mg/m² oral capecitabine administered twice daily)
Number of subjects: 251
Study 24472478 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine alone (1250 mg/m² administered twice daily)
Number of subjects: 251
Study 24472478 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone plus capecitabine
Number of subjects: 251
Study 24472478 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine alone
Number of subjects: 251
Study 21110180 — intervention group
Group type: EXPERIMENTAL
Intervention: Aidi Injection (ADI) 100 mL added to 500 mL of 5% glucose injection, administered intravenously once daily for 14 days before each course of chemotherapy (total 28 days).
Number of subjects: 60
Study 21110180 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 60
Study 18471329 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane and fentanyl
Number of subjects: 20
Study 18471329 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane and fentanyl
Number of subjects: 20
Study 16575715 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual motivation programme
Number of subjects: 142
Study 16575715 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 142
Study 12921877 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet 1 (higher carbohydrate, 72% energy)
Number of subjects: 7
Study 12921877 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet 2 (higher protein, 43% energy)
Number of subjects: 7
Study 12921877 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet 3 (higher fat, 68% energy)
Number of subjects: 7
Study 11001887 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐aza‐2'‐deoxycytidine (5‐aza‐CdR, decitabine) at doses ranging from 0.15 to 0.30 mg/kg given 5 days a week for 2 weeks
Number of subjects: 8
Study 11001887 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea (HU)
Number of subjects: 8
Study 9085393 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (made 2,567 purchase attempts)
Number of subjects: 48
Study 9085393 — intervention group
Group type: COMPARATOR
Intervention: Control group (made no purchase attempts)
Number of subjects: 48
Study 8482458 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa treatment
Number of subjects: 21
Study 4036563 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 24
Study 4036563 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy (CIT)
Number of subjects: 24
Study 29080928 — intervention group
Group type: EXPERIMENTAL
Intervention: LED-Grandio®
Number of subjects: 100
Study 29080928 — intervention group
Group type: EXPERIMENTAL
Intervention: LED-Filtek™ Supremé
Number of subjects: 100
Study 29080928 — intervention group
Group type: COMPARATOR
Intervention: Halogen-Grandio®
Number of subjects: 100
Study 29080928 — intervention group
Group type: COMPARATOR
Intervention: Halogen-Filtek™ Supremé
Number of subjects: 100
Study 27322379 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeons with high clinical experience (group C: >100 cases)
Number of subjects: 1406
Study 27322379 — intervention group
Group type: COMPARATOR
Intervention: Surgeons with low clinical experience (group A: 50 cases)
Number of subjects: 1406
Study 27322379 — intervention group
Group type: EXPERIMENTAL
Intervention: High enrollment centers (group III: >75 patients)
Number of subjects: 1406
Study 27322379 — intervention group
Group type: COMPARATOR
Intervention: Low enrollment centers (group I: <30 patients)
Number of subjects: 1406
Study 27322379 — intervention group
Group type: EXPERIMENTAL
Intervention: High annual volume centers (group 3: >75 cases)
Number of subjects: 1406
Study 27322379 — intervention group
Group type: COMPARATOR
Intervention: Low annual volume centers (group 1: <40 carotid endarterectomies)
Number of subjects: 1406
Study 24918560 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate (BT) 0.5% gel
Number of subjects: 553
Study 24918560 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 553
Study 22643538 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy
Number of subjects: 180
Study 20460620 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (500,000 IU)
Number of subjects: 2256
Study 20460620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2256
Study 18261195 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 2.5 mg
Number of subjects: 18
Study 18261195 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 10 mg
Number of subjects: 18
Study 18261195 — intervention group
Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 18
Study 15721800 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol administered before recall testing
Number of subjects: 16
Study 12641876 — intervention group
Group type: EXPERIMENTAL
Intervention: Modifiable traditional risk factors (hypertension, dyslipidemia, diabetes mellitus, poor glycemic control, smoking, physical inactivity)
Number of subjects: 0
Study 12641876 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment recommendations based on evidence from CKD populations or general population
Number of subjects: 0
Study 11006055 — intervention group
Group type: EXPERIMENTAL
Intervention: Soymilk supplementation (400 mL daily for two menstrual cycles)
Number of subjects: 60
Study 11006055 — intervention group
Group type: COMPARATOR
Intervention: Control group (no soymilk supplementation)
Number of subjects: 60
Study 8784280 — intervention group
Group type: EXPERIMENTAL
Intervention: Eutectic lidocaine/prilocaine 5% cream under occlusive dressing (Tegaderm)
Number of subjects: 106
Study 8784280 — intervention group
Group type: EXPERIMENTAL
Intervention: Eutectic lidocaine/prilocaine 5% patch
Number of subjects: 106
Study 8784280 — intervention group
Group type: COMPARATOR
Intervention: Control (lidocaine infiltration if analgesia was insufficient)
Number of subjects: 106
Study 1732427 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CP) 100 mg/m2 and Fluorouracil (5-FU) 1 g/m2 x 4
Number of subjects: 249
Study 1732427 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (CP)
Number of subjects: 249
Study 1732427 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil (5-FU)
Number of subjects: 249
Study 1732427 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CP) and Fluorouracil (5-FU) combination
Number of subjects: 249
Study 6365809 — intervention group
Group type: EXPERIMENTAL
Intervention: sfericase (6 tablets/day)
Number of subjects: 109
Study 6365809 — intervention group
Group type: EXPERIMENTAL
Intervention: sfericase (2 tablets, 3X/day)
Number of subjects: 109
Study 6365809 — intervention group
Group type: COMPARATOR
Intervention: inactive placebo
Number of subjects: 109
Study 30293937 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering drug treatment (LLT)
Number of subjects: 4257
Study 30293937 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering drug treatment (LLT) in highest risk tertile
Number of subjects: 4257
Study 30293937 — intervention group
Group type: COMPARATOR
Intervention: No LLT
Number of subjects: 4257
Study 27553762 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative instructional videos
Number of subjects: 21
Study 27553762 — intervention group
Group type: COMPARATOR
Intervention: Preoperative instructional videos
Number of subjects: 21
Study 27553762 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 21
Study 28031038 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app intervention for 4 weeks
Number of subjects: 100
Study 28031038 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (access to the app after 4 weeks)
Number of subjects: 100
Study 24438039 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 110
Study 24438039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 23099111 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Treatment (CBT)
Number of subjects: 0
Study 23099111 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Weight-Loss-Treatment (BWLT)
Number of subjects: 0
Study 19958982 — intervention group
Group type: EXPERIMENTAL
Intervention: TEVAR using GORE TAG device
Number of subjects: 59
Study 17563981 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy plus basic therapy
Number of subjects: 65
Study 17563981 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy only
Number of subjects: 65
Study 15119705 — intervention group
Group type: EXPERIMENTAL
Intervention: Condensable material Admira (group 1)
Number of subjects: 25
Study 15119705 — intervention group
Group type: COMPARATOR
Intervention: Flowable material Admira Flow (group 2)
Number of subjects: 25
Study 11549652 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg oral conjugated E
Number of subjects: 35
Study 11549652 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg droloxifene
Number of subjects: 35
Study 9625092 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sucrose diet
Number of subjects: 8
Study 9625092 — intervention group
Group type: COMPARATOR
Intervention: High-starch diet
Number of subjects: 8
Study 7932018 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplanted teeth
Number of subjects: 0
Study 7932018 — intervention group
Group type: COMPARATOR
Intervention: Control teeth
Number of subjects: 0
Study 3065099 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerulein at 100 ng/kg/h
Number of subjects: 6
Study 3065099 — intervention group
Group type: COMPARATOR
Intervention: Cerulein at 50 ng/kg/h
Number of subjects: 6
Study 29794305 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck stabilisation exercise group (NSEG; n=30)
Number of subjects: 89
Study 29794305 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck dynamic exercise group (NDEG; n=28)
Number of subjects: 89
Study 29794305 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck stabilisation and dynamic exercise group (NSDEG; n=31)
Number of subjects: 89
Study 28224367 — intervention group
Group type: EXPERIMENTAL
Intervention: MOC31PE immunotoxin administered intraperitoneally as a single dose after CRS-HIPEC with Mitomycin C
Number of subjects: 15
Study 28224367 — intervention group
Group type: EXPERIMENTAL
Intervention: MOC31PE immunotoxin
Number of subjects: 15
Study 25319807 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant interferon alfa-2b (IFN-α) therapy for 12 or 24 months
Number of subjects: 460
Study 25319807 — intervention group
Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 460
Study 25128049 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-augmented insulin pump therapy with Low Glucose Suspend (LGS)
Number of subjects: 0
Study 25128049 — intervention group
Group type: COMPARATOR
Intervention: Standard pump therapy with self-monitoring of blood glucose
Number of subjects: 0
Study 25128049 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-augmented insulin pump therapy with LGS
Number of subjects: 0
Study 22935853 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine exercise plus stabilization training for 8 weeks
Number of subjects: 30
Study 22935853 — intervention group
Group type: COMPARATOR
Intervention: Routine exercise only
Number of subjects: 30
Study 19239946 — intervention group
Group type: EXPERIMENTAL
Intervention: Incision drainage with buttoning
Number of subjects: 29
Study 19239946 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical deroofing with buttoning
Number of subjects: 29
Study 19239946 — intervention group
Group type: COMPARATOR
Intervention: Aspiration with contour dressing
Number of subjects: 29
Study 19239946 — intervention group
Group type: COMPARATOR
Intervention: Incision drainage
Number of subjects: 29
Study 17560730 — intervention group
Group type: COMPARATOR
Intervention: Mirtazapine monotherapy (n=13)
Number of subjects: 46
Study 17560730 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with mirtazapine and lithium (n=13)
Number of subjects: 46
Study 17560730 — intervention group
Group type: COMPARATOR
Intervention: Mirtazapine monotherapy (n=10)
Number of subjects: 46
Study 17560730 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with mirtazapine and carbamazepine (n=10)
Number of subjects: 46
Study 15219296 — intervention group
Group type: COMPARATOR
Intervention: Benzocaine
Number of subjects: 82
Study 15219296 — intervention group
Group type: COMPARATOR
Intervention: Viscous Lidocaine
Number of subjects: 82
Study 11570432 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet with sodium restriction
Number of subjects: 0
Study 11570432 — intervention group
Group type: COMPARATOR
Intervention: DASH diet without sodium restriction
Number of subjects: 0
Study 10036794 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% medium molecular weight hydroxyethylstarch solution made of potato (K)
Number of subjects: 20
Study 10036794 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% medium molecular weight hydroxyethylstarch solution made of corn (M)
Number of subjects: 20
Study 8817803 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 2161308 — intervention group
Group type: EXPERIMENTAL
Intervention: OVT-n (nonoxynol-9)
Number of subjects: 102
Study 2161308 — intervention group
Group type: EXPERIMENTAL
Intervention: OVT-m (menfegol)
Number of subjects: 102
Study 2161308 — intervention group
Group type: COMPARATOR
Intervention: Both OVT-n and OVT-m
Number of subjects: 102
Study 7285485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1000 mg/day)
Number of subjects: 6
Study 7285485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31739276 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioural therapy (iCBT)
Number of subjects: 82
Study 31739276 — intervention group
Group type: COMPARATOR
Intervention: Active control group (psychoeducation, monitoring and clinical support)
Number of subjects: 82
Study 31638341 — intervention group
Group type: EXPERIMENTAL
Intervention: 177 Lu-PSMA-617 (8.5 GBq decreasing by 0.5 GBq per cycle) i.v. every 6 weeks, for up to a maximum of six cycles
Number of subjects: 200
Study 31638341 — intervention group
Group type: COMPARATOR
Intervention: Cabazitaxel (20 mg/m2) i.v. every 3 weeks with prednisolone 10 mg daily orally, for a maximum of 10 cycles
Number of subjects: 200
Study 26646596 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese hand massage
Number of subjects: 100
Study 26646596 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional therapies and care)
Number of subjects: 100
Study 25637811 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (40 IU)
Number of subjects: 31
Study 25637811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 24834493 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogic practice (yogasana, pranayama, and meditation) for 3 months
Number of subjects: 64
Study 24834493 — intervention group
Group type: COMPARATOR
Intervention: Physical training (control group) for 3 months
Number of subjects: 64
Study 22945541 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage-matched care (SMC)
Number of subjects: 110
Study 22945541 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 110
Study 21195962 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous conscious sedation
Number of subjects: 80
Study 21195962 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral analgesia
Number of subjects: 80
Study 21195962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 18707659 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time feedback on forces applied during surgical tasks
Number of subjects: 12
Study 18707659 — intervention group
Group type: COMPARATOR
Intervention: Blind group (no feedback)
Number of subjects: 12
Study 17156179 — intervention group
Group type: EXPERIMENTAL
Intervention: Vouchers for 6 months of methadone treatment
Number of subjects: 126
Study 17156179 — intervention group
Group type: COMPARATOR
Intervention: Case management without vouchers
Number of subjects: 126
Study 17156179 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management
Number of subjects: 126
Study 17156179 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both interventions
Number of subjects: 126
Study 17156179 — intervention group
Group type: EXPERIMENTAL
Intervention: Vouchers alone
Number of subjects: 126
Study 17156179 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 126
Study 12838103 — intervention group
Group type: EXPERIMENTAL
Intervention: sEMG and ROM measurements before rehabilitation (n=54)
Number of subjects: 66
Study 12838103 — intervention group
Group type: EXPERIMENTAL
Intervention: sEMG and ROM measurements after rehabilitation (n=34)
Number of subjects: 66
Study 12838103 — intervention group
Group type: EXPERIMENTAL
Intervention: sEMG and ROM measurements (Part 1)
Number of subjects: 66
Study 12838103 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexion-relaxation measures
Number of subjects: 66
Study 12838103 — intervention group
Group type: EXPERIMENTAL
Intervention: sEMG for identifying abnormal motion
Number of subjects: 66
Study 10700368 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief family intervention
Number of subjects: 0
Study 10700368 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 0